Mesenchymal stem cells (MSC) are effective in treating myocardial infarction (MI) and previous reports demonstrated that hypoxia improves MSC self-renewal and therapeutics. Considering that hypoxia-inducible factor-1 alpha (HIF-1α) is a master regulator of the adaptative response to hypoxia, we hypothesized that HIF-1α overexpression in MSC could mimic some of the mechanisms triggered by hypoxia and increase their therapeutic potential without hypoxia stimulation. Transduction of MSC with HIF-1α lentivirus vectors (MSC-HIF) resulted in increased cell adhesion and migration, and activation of target genes coding for paracrine factors. When MSC-HIF were intramyocardially injected in infarcted nude rats, significant improvement was found (after treatment of infarcted rats with MSC-HIF) in terms of cardiac function, angiogenesis, cardiomyocyte proliferation, and reduction of fibrotic tissue with no induction of cardiac hypertrophy. This finding provides evidences for a crucial role of HIF-1α on MSC biology and suggests the stabilization of HIF-1α as a novel strategy for cellular therapies.
Get full access to this article
View all access options for this article.
References
1.
AndersonJL, AdamsCD, AntmanEM, BridgesCR, CaliffRM, CaseyDEJr., ChaveyWE2nd, FesmireFM, HochmanJSet al.2011. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 123:e426–e579.
2.
PatelMR, DehmerGJ, HirshfeldJW, SmithPK, SpertusJA, MasoudiFA, DehmerGJ, PatelMR, SmithPKet al.2012. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. J Thorac Cardiovasc Surg, 143:780–803.
RosovaI, DaoM, CapocciaB, LinkD, NoltaJA. 2008. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells, 26:2173–2182.
5.
SemenzaGL.2003. Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 3:721–732.
6.
LisyK, PeetDJ. 2008. Turn me on: regulating HIF transcriptional activity. Cell Death Differ, 15:642–649.
7.
MajmundarAJ, WongWJ, SimonMC. 2010. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell, 40:294–309.
8.
WangGL, JiangBH, RueEA, SemenzaGL. 1995. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A, 92:5510–5514.
9.
WengerRH.2002. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J, 16:1151–1162.
10.
GonzálezIR, Moreno-ManzanoV, Rodriguez-JimenezFJ, SepúlvedaP, Sánchez-PuellesJM. 2011. The biology of HIF proteins in cell differentiation and disease. Vitam Horm, 87:367–379.
11.
JiangC, LuH, VincentKA, ShankaraS, BelangerAJ, ChengSH, AkitaGY, KellyRA, GoldbergMA, GregoryRJ. 2002. Gene expression profiles in human cardiac cells subjected to hypoxia or expressing a hybrid form of HIF-1 alpha. Physiol Genomics, 8:23–32.
12.
KidoM, DuL, SullivanCC, LiX, DeutschR, JamiesonSW, ThistlethwaitePA. 2005. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol, 46:2116–2124.
13.
LoorG, SchumackerPT. 2008. Role of hypoxia-inducible factor in cell survival during myocardial ischemia-reperfusion. Cell Death Differ, 15:686–690.
14.
PichiuleP, ChavezJC, LaMannaJC. 2004. Hypoxic regulation of angiopoietin-2 expression in endothelial cells. J Biol Chem, 279:12171–12180.
15.
WangGL, SemenzaGL. 1993. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood, 82:3610–3615.
16.
JiL, LiuYX, YangC, YueW, ShiSS, BaiCX, XiJF, NanX, PeiXT. 2009. Self-renewal and pluripotency is maintained in human embryonic stem cells by co-culture with human fetal liver stromal cells expressing hypoxia inducible factor 1alpha. J Cell Physiol, 221:54–66.
17.
ShyuKG, WangMT, WangBW, ChangCC, LeuJG, KuanP, ChangH. 2002. Intramyocardial injection of naked DNA encoding HIF-1alpha/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc Res, 54:576–583.
MinamishimaYA, MoslehiJ, BardeesyN, CullenD, BronsonRT, KaelinWGJr.2008. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood, 111:3236–3244.
26.
ParisiQ, Biondi-ZoccaiGG, AbbateA, SantiniD, VasaturoF, ScarpaS, BussaniR, LeoneAM, PetroliniAet al.2005. Hypoxia inducible factor-1 expression mediates myocardial response to ischemia late after acute myocardial infarction. Int J Cardiol, 99:337–339.
27.
HolscherM, SilterM, KrullS, von AhlenM, HesseA, SchwartzP, WielockxB, BreierG, KatschinskiDM, ZiesenissA. 2011. Cardiomyocyte-specific prolyl-4-hydroxylase domain 2 knock out protects from acute myocardial ischemic injury. J Biol Chem, 286:11185–11194.
28.
TsaiCC, ChenYJ, YewTL, ChenLL, WangJY, ChiuCH, HungSC. 2011. Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST. Blood, 117:459–469.
29.
CeradiniDJ, KulkarniAR, CallaghanMJ, TepperOM, BastidasN, KleinmanME, CaplaJM, GalianoRD, LevineJP, GurtnerGC. 2004. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med, 10:858–864.
30.
CalvaniM, RapisardaA, UranchimegB, ShoemakerRH, MelilloG. 2006. Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood, 107:2705–2712.
31.
HigginsDF, BijuMP, AkaiY, WutzA, JohnsonRS, HaaseVH. 2004. Hypoxic induction of Ctgf is directly mediated by Hif-1. Am J Physiol Renal Physiol, 287:F1223–F1232.
32.
KellyBD, HackettSF, HirotaK, OshimaY, CaiZ, Berg-DixonS, RowanA, YanZ, CampochiaroPA, SemenzaGL. 2003. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res, 93:1074–1081.
33.
KitajimaY, IdeT, OhtsukaT, MiyazakiK. 2008. Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. Cancer Sci, 99:1341–1347.
34.
RonkainenVP, RonkainenJJ, HanninenSL, LeskinenH, RuasJL, PereiraT, PoellingerL, VuolteenahoO, TaviP. 2007. Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J, 21:1821–1830.
35.
WolfN, YangW, DunkCE, GashawI, LyeSJ, RingT, SchmidtM, WinterhagerE, GellhausA. 2010. Regulation of the matricellular proteins CYR61 (CCN1) and NOV (CCN3) by hypoxia-inducible factor-1{alpha} and transforming-growth factor-{beta}3 in the human trophoblast. Endocrinology, 151:2835–2845.
36.
JunJI, LauLF. 2010. The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. Nat Cell Biol, 12:676–685.
37.
BujakM, FrangogiannisNG. 2007. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res, 74:184–195.
38.
LiTS, HayashiM, ItoH, FurutaniA, MurataT, MatsuzakiM, HamanoK. 2005. Regeneration of infarcted myocardium by intramyocardial implantation of ex vivo transforming growth factor-beta-preprogrammed bone marrow stem cells. Circulation, 111:2438–2445.
39.
RiesC, EgeaV, KarowM, KolbH, JochumM, NethP. 2007. MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood, 109:4055–4063.
40.
GrotendorstGR.1997. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev, 8:171–179.
41.
BennewithKL, HuangX, HamCM, GravesEE, ErlerJT, KambhamN, FeazellJ, YangGP, KoongA, GiacciaAJ. 2009. The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res, 69:775–784.
42.
RecchiaAG, De FrancescoEM, VivacquaA, SisciD, PannoML, AndoS, MaggioliniM. 2011. The G protein-coupled receptor 30 is up-regulated by hypoxia-inducible factor-1alpha (HIF-1alpha) in breast cancer cells and cardiomyocytes. J Biol Chem, 286:10773–10782.
43.
GangH, HaiY, DhingraR, GordonJW, YurkovaN, AvivY, LiH, AguilarF, MarshallA, LeygueE, KirshenbaumLA. A novel hypoxia-inducible spliced variant of mitochondrial death gene Bnip3 promotes survival of ventricular myocytes. Circ Res, 108:1084–1092.
44.
HattoriK, HeissigB, TashiroK, HonjoT, TatenoM, ShiehJH, HackettNR, QuitorianoMS, CrystalRG, RafiiS, MooreMA. 2001. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood, 97:3354–3360.
45.
NeussS, BecherE, WoltjeM, TietzeL, Jahnen-DechentW. 2004. Functional expression of HGF and HGF receptor/c-met in adult mesenchymal stem cells suggest arole in cell mobilization, tissue repair and wound healing. Stem cells, 22:405–414.
46.
WojakowskiW, TenderaM, MichalowskaA, MajkaM, KuciaM, MaslankiewiczK, WyderkaR, OchalaA, RatajczakMZ. 2004. Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation, 110:3213–3220.
47.
RajagopalanS, OlinJ, DeitcherS, PieczekA, LairdJ, GrossmanPM, GoldmanCK, McEllinK, KellyR, ChronosN. 2007. Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience. Circulation, 115:1234–1243.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
